Company intelligence / Profile preview

SM Biomed

Sungai Petani, Kedah, Malaysia

Ownership: Private
Development stage: Other

Overview

SM Biomed is Malaysia’s largest manufacturer of APIs with a strong regulatory record, exporting globally, and maintains USFDA, EuGMP, TGA, KFDA, and NPRA certifications. Its core focus is on macrolide antibiotics, glucocorticoids, anti-diabetic agents, and PDE5 inhibitors, supplying over 500 clients across 60+ countries. Its erythromycin APIs hold DMF and CEP designations and are produced in state-of-the-art multipurpose GMP facilities.[1][3][5]

Therapeutic areas: ImmunologyEndocrinologyMen's HealthInfectious DiseasesHematology
Modalities: Small molecule
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on SM Biomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SM Biomed.

Explore the full profile